Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
630.00    30.00 (5.00%)
Bid:
626.00
Ask:
634.00
Spread: 8.00 (1.278%)
Market Cap: £762.36m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Block Listing Return

7 Jan 2020 10:17

RNS Number : 9931Y
Oxford Biomedica PLC
07 January 2020
 

For Immediate Release

07 January 2020

 

OXFORD BIOMEDICA PLC

 

BLOCK LISTING RETURN

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

2015 Employee Share Option Scheme

Period of return:

From:

1 July 2019

To:

31 December 2019

Balance of unallotted securities under scheme(s) from previous return:

31,157

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

20,301

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

10,856

 

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

2015 Long Term Incentive Plan

Period of return:

From:

1 July 2019

To:

31 December 2019

Balance of unallotted securities under scheme(s) from previous return:

270,875

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

270,875

 

 

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

2015 Deferred Bonus Plan

Period of return:

From:

1 July 2019

To:

31 December 2019

Balance of unallotted securities under scheme(s) from previous return:

102,346

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

102,346

 

 

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

Sharesave Scheme

Period of return:

From:

1 July 2019

To:

31 December 2019

Balance of unallotted securities under scheme(s) from previous return:

237,224

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

78,180

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

159,044

 

 

 

Name of contact:

Natalie Walter

Telephone number of contact:

01865 783000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRBRMMTMTBMBIM
Date   Source Headline
20th Dec 201711:22 amRNSDirector Dealings / Market Share Purchase
11th Dec 20177:08 amRNSPrimary analysis results from JULIET trial
1st Dec 201710:16 amRNSTotal Voting Rights
23rd Nov 201711:29 amRNSDirector Dealings / Market Share Purchase
9th Nov 20177:00 amRNSOXB to present at Jefferies Healthcare Conference
6th Nov 201712:06 pmRNSHoldings in Company
6th Nov 20177:37 amRNSCTL019 MAA submission to the EMA
1st Nov 20179:19 amRNSTotal Voting Rights
31st Oct 20174:01 pmRNSKymriah submitted to FDA for adults with r/r DLBCL
23rd Oct 201711:27 amRNSDirector Dealings / Market Share Purchase
2nd Oct 201711:21 amRNSTotal Voting Rights
26th Sep 20172:55 pmRNSDirector Dealings / Market Share Purchase
26th Sep 20179:37 amRNSLong Term Incentive Plan Option Grant
25th Sep 20173:05 pmRNSBlock listing application
25th Sep 20179:46 amRNSCantor Fitzgerald Healthcare Conference 2017
22nd Sep 201712:36 pmRNSDirector Dealings
20th Sep 20173:25 pmRNSHolding(s) in Company
19th Sep 20178:58 amRNSDirector Dealings
15th Sep 20179:21 amRNSDirector/PDMR Shareholding
12th Sep 20177:15 amRNSHardman Research: New advanced therapies era
7th Sep 201710:11 amRNSHoldings in Company
5th Sep 201711:45 amRNSDirector/PDMR Shareholding
5th Sep 201711:39 amRNSDirector/PDMR Shareholding
5th Sep 20177:00 amRNSOXB to Present at Rodman & Renshaw Conference
1st Sep 20179:25 amRNSTotal Voting Rights
30th Aug 20174:34 pmRNSCTL019 receives FDA approval
29th Aug 20177:00 amRNSStuart Paynter starts as new CFO
24th Aug 201710:41 amRNSHardman Research: Ready for CTL019 approval
23rd Aug 201710:31 amRNSDirector Dealings / Market Share Purchase
22nd Aug 201710:35 amRNSDirector Dealings / Market Share Sale and Purchase
17th Aug 20177:00 amRNSInterim Results
11th Aug 20177:00 amRNSOXB announces Innovate UK £2m collaboration
7th Aug 20179:05 amRNSHolding(s) in Company
7th Aug 20177:00 amRNSMHRA Licence For Commercial Supply
1st Aug 20179:19 amRNSTotal Voting Rights
25th Jul 20177:00 amRNSNotice of Interim Results
24th Jul 201710:10 amRNSDirector Dealings / Market Share Purchase
18th Jul 20178:47 amRNSDirector Dealings / Market Share Sale and Purchase
14th Jul 20174:49 pmRNSDirector/PDMR Shareholding
14th Jul 20173:30 pmRNSPDMR Shareholding
14th Jul 201711:41 amRNSLTIP for Long Term Incentive Plan
13th Jul 201712:38 pmRNSDirector Dealings / Market Share Sale and Purchase
13th Jul 20177:15 amRNSHoldings in Company
13th Jul 20177:00 amRNSFDA AdCom Recommends CTL019 for Approval
11th Jul 20179:29 amRNSDirector Dealings / Market Share Sale and Purchase
7th Jul 201710:15 amRNSHardman Research: Major deal to supply Novartis
6th Jul 20177:15 amRNSHolding(s) in Company
6th Jul 20177:00 amRNSMajor Commercial and Clinical Supply Agreement
3rd Jul 20172:20 pmRNSTotal Voting Rights
3rd Jul 20172:18 pmRNSBlock Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.